Search research articles
Contact Us
Filters
Showing results (201-210 of 304) with videos related to
Page
of 31
Sort By:
Journal of Cancer Research and Clinical Oncology
|
April 13, 2018
MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach
Hans-Joachim Schmoll, Dirk Arnold, Aimery de Gramont, et al.
Current Colorectal Cancer Reports
|
September 14, 2013
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
Thierry André, Timothy Iveson, Roberto Labianca, et al.
Clinical Colorectal Cancer
|
June 13, 2026
Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database
Thomas Samaille, Morteza Raeisi, Romain Cohen, et al.
American Journal of Hematology
|
June 15, 2017
Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU)
Thomas E Witzig, Patrick B Johnston, Betsy R LaPlant, et al.
Clinical Colorectal Cancer
|
February 19, 2008
Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer
Hendrik-Tobias Arkenau, Ullrich Graeven, Stephan Kubicka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 19, 2012
Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas
Harry H Yoon, Qian Shi, William R Sukov, et al.
Journal of the National Cancer Institute
|
November 1, 2014
ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer
Lindsay A Renfro, Axel Grothey, Yuan Xue, et al.
The Oncologist
|
September 28, 2012
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study
Johanna C Bendell, Tanios S Bekaii-Saab, Allen L Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2010
Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7
Axel Grothey, Daniel A Nikcevich, Jeff A Sloan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database
Qian Shi, Thierry Andre, Axel Grothey, et al.
Page
of 31
Search research articles
Search
Showing results (201-210 of 304) with videos related to
Sort By:
Page
of 31
Journal of Cancer Research and Clinical Oncology
|
April 13, 2018
MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach
Hans-Joachim Schmoll, Dirk Arnold, Aimery de Gramont, et al.
Current Colorectal Cancer Reports
|
September 14, 2013
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
Thierry André, Timothy Iveson, Roberto Labianca, et al.
Clinical Colorectal Cancer
|
June 13, 2026
Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database
Thomas Samaille, Morteza Raeisi, Romain Cohen, et al.
American Journal of Hematology
|
June 15, 2017
Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU)
Thomas E Witzig, Patrick B Johnston, Betsy R LaPlant, et al.
Clinical Colorectal Cancer
|
February 19, 2008
Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer
Hendrik-Tobias Arkenau, Ullrich Graeven, Stephan Kubicka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 19, 2012
Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas
Harry H Yoon, Qian Shi, William R Sukov, et al.
Journal of the National Cancer Institute
|
November 1, 2014
ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer
Lindsay A Renfro, Axel Grothey, Yuan Xue, et al.
The Oncologist
|
September 28, 2012
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study
Johanna C Bendell, Tanios S Bekaii-Saab, Allen L Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2010
Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7
Axel Grothey, Daniel A Nikcevich, Jeff A Sloan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database
Qian Shi, Thierry Andre, Axel Grothey, et al.
Page
of 31